Recent results from a trial known as the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST), showing that patients with severe carotid artery stenosis suffered similar rates of adverse events in both stenting and endarterectomy procedures, are evidence that stenting will continue to remain competitive with surgical treatment, says an analyst with research and consulting firm GlobalData.
The 10-year findings of the trial, published by the New England Journal of Medicine, showed adverse event rates of 11.8% in stenting and 9.9% in endarterectomy groups, with no significant difference in restenosis rates. In this way, both procedures exhibit similar long-term, post-procedural safety and efficacy profiles.
Premdharan Meyyan, GlobalData’s Analyst covering Medical Devices, states that in order for stenting to experience increased uptake, developers should prioritize improving solutions for embolic protection to minimize periprocedural stroke risk.
The analyst adds that mesh-covered stents are also emerging as a potential solution to the periprocedural stroke rate. InspireMD has developed the CE-marked CGuard nitinol stent, which utilizes a polyethylene terephthalate mesh to provide continuous embolic protection, showing 100% procedural success and no major adverse events at the 30-day mark.